JACC
HOME SUBSCRIPTIONS CURRENT ISSUE PAST ISSUES CARDIOSOURCE SEARCH HELP FEEDBACK
 QUICK SEARCH:   [advanced]


     


J Am Coll Cardiol, 2001; 38:1711-1717
© 2001 by the American College of Cardiology Foundation
This Article
Right arrow Abstract Freely available
Right arrow Figures Only
Right arrow Full Text (PDF)
Right arrow Alert me when this article is cited
Right arrow Alert me if a correction is posted
Services
Right arrow Email this article to a friend
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Download to citation manager
Citing Articles
Right arrow Citing Articles via HighWire
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by Greenwood, J. P.
Right arrow Articles by Mary, D. A. S. G.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Greenwood, J. P.
Right arrow Articles by Mary, D. A. S. G.

CLINICAL STUDY

Hypertensive left ventricular hypertrophy: relation to peripheral sympathetic drive

John P. Greenwood, PhD, MBChB*,a, Eleanor M. Scott, BS, BM, BMedScia, John B. Stoker, BSc, MBChBa and David A. S. G. Mary, PhD, MBChBa

a Department of Cardiology, St. James’s University Hospital, Leeds, United Kingdom

Manuscript received October 31, 2000; revised manuscript received July 20, 2001, accepted August 15, 2001.

* Reprint requests and correspondence: Dr. John P. Greenwood, Department of Cardiology, St. James’s University Hospital, Beckett Street, Leeds, LS9 7TF, United Kingdom
john_greenwood{at}hotmail.com


    Abstract
 Top
 Abstract
 Methods
 Results
 Discussion
 References
 
OBJECTIVES

This study was designed to examine whether the occurrence of left ventricular hypertrophy (LVH) in moderate to severe essential hypertension (EHT) was associated with alteration in peripheral sympathetic drive.

BACKGROUND

In hypertension, LVH is an independent predictor of increased morbidity and mortality. The reported mechanisms leading to LVH remain unclear but include hemodynamic and humoral factors. The sympathetic nervous system may be important, particularly as catecholamines have been shown to have trophic properties. We tested the hypothesis that sympathetic activity measured using microneurography could be different in patients with hypertension depending on the presence of LVH.

METHODS

We examined 28 subjects with moderate to severe EHT (stages 2 to 3; Joint National Committee [JNC]-VI classification). Fourteen had echocardiographic evidence of LVH (EHT + LVH), while the other 14 subjects (EHT) did not. Subjects were matched in terms of age, body mass index and levels of arterial blood pressure. Peripheral muscle sympathetic nerve activity was measured from both multiunit bursts (MSNA) and single unit (s-MSNA) vasoconstrictor impulses via the peroneal nerve.

RESULTS

The mean frequency of s-MSNA and MSNA was greater in the EHT + LVH group than it was in the EHT group (mean ± SEM; 75.9 ± 6.9 impulses/100 beats vs. 52.1 ± 2.9 impulses/100 beats, p < 0.001 and 64.2 ± 5.7 bursts/100 beats vs. 48.9 ± 2.8 bursts/100 beats, p < 0.05).

CONCLUSIONS

These results indicate that, in subjects with moderate to severe hypertension, the presence of LVH is associated with higher sympathetic discharge, evidenced by an increase in unitary firing frequency and also by fiber recruitment.

Abbreviations and Acronyms
  EHT = essential hypertension
  EHT + LVH = essential hypertension with left ventricular hypertrophy
  IVS = intraventricular septal thickness
  JNC = Joint National Committee
  LVH = left ventricular hypertrophy
  LVID = left ventricular internal diameter
  LVM = left ventricular mass
  LVMI = left ventricular mass index
  MSNA = multiunit muscle sympathetic nerve activity
  PW = end-diastolic posterior wall thickness
  s-MSNA = single-unit muscle sympathetic nerve activity


In patients with hypertension, the occurrence of left ventricular hypertrophy (LVH) has been associated with an increase in mortality from all cardiovascular causes (1–4). However, not all subjects go on to develop LVH, and the reasons for this remain undetermined. The development of LVH has been attributed to many factors, including raised arterial pressure levels (resulting in increased myocardial workload) and growth-promoting substances such as angiotensin II, insulin-like growth factor-1 and circulating catecholamines (5–10).

In essential hypertension (EHT), the elevated arterial pressure has been associated with increased central sympathetic output to the heart, kidney and skeletal muscles (11–13). In humans, a direct assessment of sympathetic activity can be performed using the technique of microneurography. This technique measures muscle sympathetic nerve activity (MSNA) via the assessment of the mean frequency of multiunit MSNA bursts (14,15) or from single unit vasoconstrictor activity (s-MSNA) (16,17).

It has been suggested that the severity of hypertension is related to the magnitude of increased sympathetic drive (15). However, other studies have not demonstrated this relationship (18,19), and, more recently, we have shown that, in stage 1 hypertensive disease, the peripheral sympathetic drive is, in fact, higher than that found in the more severe degrees of hypertension (16). In accounting for these differences, one should bear in mind that in the earlier study (15) the presence LVH was not taken into account.

Thus, it remains unknown whether hypertensive patients who have developed LVH have altered sympathetic drive compared with those without LVH who have similar blood pressure levels. Indeed, it is known that patients with hypertension who have peripheral vascular disease have a greater degree of LVH than those without LVH (20) and that increased sympathetic drive enhances vascular hypertrophy (10). This supports the hypothesis that patients with hypertension and end-organ damage may have evidence of more severe and widespread sympathetic hyperactivity.

Therefore, this investigation was designed to see whether in EHT the presence of LVH was associated with altered central sympathetic drive to the periphery at rest. In addition to multiunit microneurographic recordings, single unit discharge was obtained as this allows further insight into the mechanisms of central autonomic control. Two groups of patients with hypertension were examined, either with or without LVH, and they were closely matched in terms of age, body weight and, in particular, arterial blood pressure levels.


    Methods
 Top
 Abstract
 Methods
 Results
 Discussion
 References
 
Subjects.   The study involved Caucasian patients with newly diagnosed EHT who were examined between January 1998 and May 1999. The study group was recruited from among 34 patients; in 6 patients it was not possible to obtain stable microneurographic data. All patients were screened by history, physical and laboratory examination. Patients were excluded if there was evidence of secondary hypertension, arrhythmia or chronic disease that may influence the autonomic nervous system. Fourteen patients (six male) had hypertension complicated by LVH (EHT + LVH), and their arterial blood pressure values, based on the average of at least three readings taken on separate occasions, indicated a severity of hypertension within stage 2 or 3 of the Joint National Committee (JNC)-VI classification (21), as summarized in the following text.

  1. Stage 1: Systolic blood pressure of 140 to 159 mm Hg or diastolic blood pressure of 90 to 99 mm Hg.
  2. Stage 2: Systolic blood pressure of 160 to 179 mm Hg or diastolic blood pressure of 100 to 109 mm Hg.
  3. Stage 3: Systolic blood pressure of ≥180 mm Hg or diastolic blood pressure of ≥110 mm Hg.

Over the same period of time, a second group of 14 patients (9 male) with EHT without signs of LVH were studied, and these were matched in terms of age, body weight, body mass index and levels of arterial blood pressure.

Electrocardiographic voltage criteria were used to identify subjects with suspected LVH, and left ventricular dimensions were measured using two-dimensional M-mode echocardiography (Toshiba Powervision SSA-380A, Toshiba Corp., Japan). Using American Society of Echocardiography recommendations (22), measurements of end-diastolic posterior wall thickness (PW), left ventricular internal diameter (LVID) and intraventricular septal thickness (IVS) were determined and considered to represent LVH if measures of PW or IVS exceeded 11 mm. Left ventricular mass (LVM) was calculated according to the Penn convention (23) using the equation: and, to account for body surface area, left ventricular mass index (LVMI) was derived.

Of the 14 patients with EHT + LVH, 8 had stage 2 and 6 had stage 3 disease. Due to the severity of disease, some individuals had already been commenced on oral antihypertensive therapy (between two and four months) before taking part in the study. It was felt unethical to perform a prolonged washout period before these studies, so treatment was only omitted on the study day. Of these 14 patients, 6 were receiving treatment that consisted of diuretics (n = 2), the beta-blocking agent atenolol (n = 2), angiotensin-converting enzyme inhibitors (n = 3) and calcium antagonists (n = 1). The 14 patients with EHT (seven each with stage 2 and stage 3 disease) who did not have evidence of LVH were examined before commencing antihypertensive therapy.

General protocol.   Under the approval of St. James’s University Hospital Ethics Committee, subjects provided informed written consent to the investigation. All subjects were studied between the hours of 9 AM and 12:00 midday and were asked to avoid nicotine and caffeine products for 12 h and alcohol and strenuous exercise for 24 h before the investigation. Subjects maintained a normal dietary intake of sodium, and they were requested to have had a light breakfast and to empty their bladder before commencing the study.

During each session, subjects were studied in the semisupine position. Measurements were made in a darkened laboratory in which the temperature was constant at 22 to 24°C. Heart rate and arterial blood pressure were monitored and recorded using a standard electrocardiogram and a Finapres device (Model 2300; Ohmeda, Hatfield, Herts, United Kingdom) applied to the middle finger at the level of the heart. A pneumograph consisting of a corrugated rubber tube connected to a pressure transducer was used to monitor and record respiration. Subjects were asked to relax and not speak for 10 min so as to reach a steady state, after which time hemodynamic and microneurographic data were obtained for repeated baseline resting measurements of at least 5-min duration.

Microneurography.   Postganglionic muscle sympathetic nerve activity was recorded from the right peroneal nerve as previously described in detail (14,16). Briefly, the neural signal was amplified (x50,000), and, for the purpose of generating bursts representing multiunit discharge, the signal was filtered (bandwidth of 700 to 2,000 Hz) and integrated (time constant 0.1 s). The output of action potentials and bursts from this assembly were passed to a data-acquisition system (FASTDAQ, Lectromed UK Ltd., Letchworth Garden City, Herts, United Kingdom) for on-line monitoring and storage using a minicomputer (Elonex UK Ltd., Bradford, United Kingdom). The FASTDAQ system digitized the action potentials at 12,000 samples/s and all other data channels at 2,000 samples/s (8 bits). Long-term storage was achieved using a high-capacity drive (Iomega zip drive, Iomega Europe GmbH, Freiburg, Germany).

With the exploring electrode in the nerve, electrical stimulation (0.1 to 1.0 V, 1 Hz, 0.2 ms) caused muscular twitches without paraesthesia. Multiunit muscle sympathetic nerve activity was differentiated from skin sympathetic activity and afferent activity by previously accepted criteria (14). Single units were sought by repeatedly making tiny adjustments to the exploring electrode position. When a unit was identified in the raw action potential neurogram as being different in height from other concomitant units (if present), it was further scrutinized to confirm it had vasoconstrictor properties, as described in the section entitled "Other procedures." Fast monitor sweep and an on-line storage oscilloscope were then used to confirm the presence of a single unit by demonstrating consistency in action potential morphology as previously described (16,17).

Other procedures.   Only vasoconstrictor activity was accepted and examined, the criteria of acceptance being appropriate responses to spontaneous changes in arterial blood pressure, the Valsalva maneuver and isometric hand-grip exercise, as previously described (16,17). Briefly, during Valsalva, sympathetic activity increased during the latter part of phase II or phase III and decreased during phase IV (increase and overshoot of blood pressure). Isometric hand-grip exercise, performed using a dynamometer (MIE Medical Research Ltd., Leeds, United Kingdom) produced a late increase in arterial blood pressure, sympathetic neural activity and calf vascular resistance. Calf vascular resistance was determined from the product of mean arterial pressure on the mean of at least six measurements of calf blood flow in the left leg using strain-gauge plethysmography (DE Hokansen Inc., Bellevue, Washington). In each subject the resting mean frequencies of s-MSNA impulses and MSNA bursts were obtained simultaneously.

Data analysis.   Without knowledge of the patient diagnosis, data analysis was performed off-line by a single experienced operator using signal-processing software (FASTDAQ, Lectromed UK Ltd.). Mean data from at least three baseline time periods were analyzed. An electronic discriminator was used to count the spikes of s-MSNA and the R-wave of the electrocardiogram (Fig. 1). The former was quantified as mean frequency of impulses/min and impulses/100 cardiac beats. The bursts of MSNA on the mean voltage neurogram were identified by inspection, being defined by amplitude when the signal-to-noise ratio was >3, and they were quantified as mean number of bursts/min and bursts/100 cardiac beats. Neural activity was expressed both per min and per 100 cardiac beats as it is understood that there is a complex relationship between heart rate and sympathetic discharge frequency, and the latter expression avoids any interference by the length of the cardiac cycle (24).



View larger version (27K):
[in this window]
[in a new window]
 
Figure 1 Example of recordings from a patient with hypertension. From above and moving down are shown the electrocardiogram (ECG), respiratory movements (Resp), Finapress blood pressure (FBP), multiunit muscle sympathetic nerve activity (Bursts) and action potentials (AP in µV). The single-unit muscle sympathetic nerve activity is counted from APs of the same profile and amplitude (tallest unit in this example) to derive the mean frequency of central vasoconstrictor sympathetic neural discharge. The burst count may include a variable number of units with different profiles.

 
Statistics.   Two-way analysis of variance (ANOVA) with Bonferroni multiple post-test comparisons were used to compare data between the two groups. The least square technique was used for assessing the linear relationship between variables. Values of p <0.05 were considered statistically significant. Data were presented as mean ± SEM.


    Results
 Top
 Abstract
 Methods
 Results
 Discussion
 References
 
The demographic details of the two matched groups are shown in Table 1. There was no significant difference in age, body weight, body mass index, heart rate or arterial blood pressure between the groups.


View this table:
[in this window]
[in a new window]
 
Table 1 Demographic Details of the Two Subject Groups

 
As expected, there was a significant positive correlation (r) for resting s-MSNA and MSNA with the subjects age (r at least 0.42 and at most 0.59; p < 0.0002). However, there was no significant correlation within any group (consistently r < 0.38, p > 0.09) between resting sympathetic discharge (s-MSNA or MSNA) and the levels of resting arterial blood pressure (systolic, diastolic or mean pressure) or heart rate.

Respectively, for the EHT + LVH and the EHT groups, posterior wall thickness was 13 ± 0.8 mm and 10 ± 0.3 mm (p < 0.05); interventricular septal thickness was 12 ± 0.8 mm and 10 ± 0.3 mm (p > 0.05), and end-diastolic volumes were 124 ± 12.4 ml and 127 ± 15.8 ml (p > 0.8). The estimated LVM in the EHT + LVH group was 301 ± 26.6 g and in the EHT group was 215 ± 19 g (p < 0.05), and the values for LVMI when indexed by body surface area were 155 ± 13 g/m2 and 113 ± 10.9 g/m2 for the two groups, respectively (p < 0.05). Using two-way ANOVA, no significant interaction was found between any of these variables (p > 0.3).

Resting s-MSNA in EHT + LVH was greater than that in EHT; on average this represented a 34% and a 46% increase when activity was expressed per minute and per 100 cardiac beats (Fig. 2). The group mean frequency of s-MSNA in EHT + LVH versus EHT was 51.1 ± 5.3 impulses/min versus 38.1 ± 2.4 impulses/min (p > 0.05) and 75.9 ± 6.9 impulses/100 beats versus 52.1 ± 2.9 impulses/100 beats (p < 0.001). In addition, the group of EHT + LVH had greater resting MSNA than the EHT group (Fig. 3), respectively; on average this represented a 14% and 31% increase when activity was expressed per minute and per 100 cardiac beats. The group mean frequency of MSNA in EHT + LVH versus EHT was 40.6 ± 2.5 bursts/min versus 35.5 ± 2.1 bursts/min (p > 0.05) and 64.2 ± 5.7 bursts/100 beats versus 48.9 ± 2.8 bursts/100 beats (p < 0.05). Two-way ANOVA of these variables showed there was no significant interaction (p > 0.15). When only the 22 untreated patients were considered (8 in the EHT + LVH group vs. 14 in the EHT group), the overall findings were unaltered in that the LVH group still had significantly greater sympathetic discharge compared with the non-LVH group. Within the group of EHT + LVH, there was no significant difference in any measure of sympathetic discharge between those who were treated and those untreated (Figs. 2 and 3). Finally there was a significant correlation between both s-MSNA and MSNA (quantified per 100 cardiac beats) and LVMI (always p < 0.05; r = 0.48 and r = 0.46, respectively).



View larger version (15K):
[in this window]
[in a new window]
 
Figure 2 Scatter-graph showing the mean frequency of single-unit muscle sympathetic nerve activity (s-MSNA) in essential hypertensives with left ventricular hypertrophy (LVH) (triangles) and without LVH (squares). Open triangles = those subjects receiving therapy; bars = the group mean. *p < 0.001 (two-way analysis of variance). NS = nonsignificant.

 


View larger version (14K):
[in this window]
[in a new window]
 
Figure 3 Scatter-graph showing the mean frequency of multiunit muscle sympathetic nerve activity (MSNA) in essential hypertensives with left ventricular hypertrophy (LVH) (triangles) and without LVH (squares). Open triangles = those subjects receiving therapy; Bars = the group mean. {dagger}p < 0.05 (two-way analysis of variance). NS = nonsignificant.

 

    Discussion
 Top
 Abstract
 Methods
 Results
 Discussion
 References
 
This is the first evidence that the mean resting frequency of peripheral sympathetic vasoconstrictor discharge in moderate to severe hypertension was greater in those patients with LVH compared with those without LVH. This relative sympathetic hyperactivity reflected an increased central output at rest and was not caused by differences in arterial blood pressure, age or body weight. These findings allow us to hypothesize that patients with relatively higher central sympathetic output may be more likely to develop LVH than those with equivalent severity of hypertension who have lower sympathetic output.

Microneurography.   Microneurography is a well-established technique that has been used successfully in the assessment of peripheral sympathetic activity (14). Previous studies have examined the frequency and incidence of MSNA bursts derived from multiunit recordings but have not been specific to any of the individual action potentials that constitute the burst. Despite the difficulty of establishing that every unit within a burst has a vasoconstrictor role, there is a wealth of evidence to suggest that patients with hypertension have a greater frequency of MSNA bursts than properly matched normotensive subjects (15,25–27).

More recently, recordings of single unit muscle sympathetic discharge have been obtained from normotensive and hypertensive subjects (16,17). Though more difficult to obtain than MSNA bursts, the advantage of directly measuring the mean frequency of a single unit discharge is that it may be a reflection of the true resting central sympathetic output to the periphery. This is because it allows quantification from specific units with demonstrable vasoconstrictor function without interference from other uncharacterized units. In addition, it can avoid the inclusion of recruited units, which could otherwise be counted during the recording of MSNA bursts. Finally, although the technique of microneurography is selective for the particular unit(s) studied, under resting conditions the variability between repeat recordings of both s-MSNA and MSNA is <8% (16).

In this study we measured both the resting mean frequency of multiunit MSNA bursts and single unit discharge. Qualitatively, both measures responded to reflex maneuvers in a manner that reflected their involvement in peripheral vascular control. The results obtained from MSNA recordings in this study were similar to those previously published in age-comparable hypertensive subjects (15,16,25,26,28). This can be considered a reflection of the stringent study protocol and the attempts to avoid confounding factors. As previously discussed (16), it is known that many biological factors can influence sympathetic output such as age, obesity and severity of hypertension, as well as environmental factors including dietary sodium intake, alcohol, nicotine and exercise. Thus subjects in the two groups were closely matched for biological variables and were studied under the same laboratory conditions. Although there was a significant difference in LVM between the two groups, there was a degree of overlap in the data. This relates, in part, to the variability of left ventricular internal diameter and the requirement of an increase in wall thickness for a patient to be considered as having LVH. This overlap could not be avoided, as it was important that subjects were matched for biological variables and not excluded on the basis of cavity or wall dimensions. However, even if we hypothesize that the EHT group had some degree of LVH (to explain the overlap), it remains valid that the EHT + LVH group with a greater degree of LVH have greater sympathetic activation. In fact, this is further supported by the fact that there was a positive correlation between LVMI and sympathetic nerve activity.

Main findings.   In this study, the resting mean discharge frequency of s-MSNA per 100 cardiac beats in the patients with EHT + LVH was significantly greater (by about 46%) than that in the EHT group. Assessment from multiunit MSNA bursts revealed that the EHT + LVH group still had about 31% greater sympathetic activity than the EHT group. Although there was a similar trend regarding the mean discharge frequency per minute of both measures of sympathetic activity, the differences did not reach statistical significance. This increase in both single unit and multiunit sympathetic discharge demonstrates two potential mechanisms for central sympathetic regulation. First, increased s-MSNA represents a true increase in the discharge frequency of central sympathetic neurons. Second, increased MSNA represents central activation as well as reflex-based increases (fiber recruitment) in sympathetic activity.

In interpreting these results, it is important to take into consideration that some of the subjects with LVH were on antihypertensive medication, some of which can lower heart rate. It is well known that differences in the pulse interval can affect the assessment of mean sympathetic discharge frequency (24). Thus, considering the data over 100 heart beats to allow for differences in resting heart rate, assessment of both MSNA and s-MSNA demonstrated clear differences between the groups. Furthermore, if one considers only those subjects not receiving antihypertensive therapy, then the group resting heart rates were similar, and the overall findings of sympathetic discharge were unaltered. In addition, it has been reported that beta-blockers have a variable effect on sympathetic discharge. Acute intravenous administration can increase sympathetic discharge, presumably as a result of acute blood pressure lowering and baroreceptor reflex activation. However, chronic administration, as in this study, with agents such as atenolol (29) and metoprolol (30) may, respectively, have either no effect on or reduce the resting mean frequency of sympathetic discharge in EHT. Also, treatment with angiotensin-converting enzyme inhibitors in hypertension has been shown to have either no effect or decrease sympathetic nerve traffic (31,32). Therefore, the increased activity in EHT + LVH was not attributable to antihypertensive treatment and, in fact, was still apparent despite the use of agents that may have attenuated the group differences, thus adding further weight to the findings.

Previous investigators have suggested a positive correlation between MSNA and the severity of hypertensive disease (15). More recently, we have shown that patients with moderate to severe hypertension had either lower or equal sympathetic output compared with matched groups with milder hypertension, depending on whether single units or multiunits were examined (16). There are a number of reasons that may account for these different findings. First, blood pressure classification differed between the studies, the former using an arbitrary classification and the latter using the JNC-VI classification (21). Secondly, we have shown that the ability to record neural activity from a single sympathetic unit allows further insight into central command, as it allows a true assessment of central sympathetic discharge frequency. Thus, using a combination of single and multiunit assessment may have allowed further characterization of the hypertensive subjects. Finally, and perhaps most importantly, subjects with severe hypertension in the former study had a high LVMI, whereas, in the latter study, LVH was excluded. Thus, the apparent contradictory results in these two studies can be explained in a manner entirely consistent with the current findings. The results of this investigation suggest that the occurrence of LVH in EHT is associated with an increase in magnitude of the sympathetic hyperactivity compared with that in subjects without LVH.

These findings also help to reconcile differing reports on sympathetic hyperactivity in hypertension. On the one hand it has been reported that peripheral sympathetic hyperactivity mainly occurred in borderline/mild hypertension (16,25,27,33) as well as in younger patients (11,13,27). These findings have provided support to the theory that the onset of hypertension is associated with sympathetic hyperactivity, while, eventually, the severity of hypertension is maintained, in part, by the occurrence of end-organ structural changes (11,34). On the other hand, marked peripheral sympathetic hyperactivity has also been reported in patients with severe hypertension (15). The finding that established hypertension complicated by LVH is associated with a more marked sympathetic hyperactivity than uncomplicated hypertension of equal severity suggests the possibility of different subgroups within the hypertensive population. Given that arterial pressure is modulated by various central, reflex, hormonal and structural changes as well as by sympathetic drive (11,12,34), it may be reasonable to postulate that patients destined to develop LVH or vascular hypertrophy are more likely to maintain, or further increase, their marked sympathetic hyperactivity. In support of this, catecholamines have been shown experimentally to have trophic properties on cardiac myocytes (35) and in the intact animal heart (36). Also, in human studies, indexes of LVM have tended to correlate with plasma norepinephrine values (37) and cardiac noradrenaline spillover (38). However, we must also consider an opposing viewpoint, that is, the presence of LVH may lead to the increase in peripheral sympathetic activity. This situation could potentially arise via the altered stimulation of cardiac afferent fibers in the hypertrophied ("stiff") ventricle. This maybe less likely, as recent experimental evidence suggests that isolated ventricular distension has only a small effect on systemic perfusion pressure (vascular resistance) until distension is excessive (39). Also, a stiffer left ventricle could lead to atrial distension, but stimulation of mechanoreceptors in the walls of the atria and vein-atrial junctions has been shown not to affect the discharge in peripheral sympathetic nerves (40).

Study limitations.   The fundamental problem of all studies of human autonomic control is the constraint imposed by the limited techniques available to actually quantify sympathetic activity. Although microneurography has been considered the only technique available to "directly" record sympathetic activity in human subjects, recordings are made from a peripheral nerve. It is known that reflex activation of the sympathetic system is heterogeneous in nature; however, this study was performed in the baseline resting state. In addition, although elegant techniques for the assessment of cardiac sympathetic function utilizing norepinephrine spillover are available, by their invasive nature they still have methodologic constraints. Importantly, however, evidence does suggest that measures of cardiac norepinephrine spillover do correlate well with recordings of peripheral sympathetic nerve activity (41). One final point to remember is that this was a cross-sectional study, which, although it implies an association, gives no direct evidence of causality. There are many additional factors known to be important in the development of LVH, but, in light of the current findings, the occurrence of LVH needs to be considered in future studies involving sympathetic assessment in hypertensive disease.

Conclusions.   This is the first evidence that, in patients with moderate to severe EHT, the presence of LVH is associated with higher resting sympathetic discharge, evidenced by both an increase in unitary firing frequency and by fiber recruitment. This supports the hypothesis that central sympathetic hyperactivity may be a factor in the development of hypertensive LVH.


    Acknowledgments
 
The authors thank Mr. J. Bannister, Mrs. J. Corrigan and Mrs. G. McGawley for their technical assistance and Dr. A. Brown, Dr. P. Robinson and Dr. N. Bishop for assisting with patient recruitment.


    Footnotes
 
Supported, in part, by the British Heart Foundation (Grant No. FS/97085).


    References
 Top
 Abstract
 Methods
 Results
 Discussion
 References
 

  1. Levy D, Garrison RJ, Savage DD, Kannel WB, Castelli WP. Prognostic implications of echocardiographically determined left ventricular mass in the Framingham Heart study. N Engl J Med. 1990;322:1561–1566[Abstract]
  2. Koren MJ, Devereux RB, Casale PN, Savage DD, Laragh JH. Relation of left ventricular mass and geometry to morbidity and mortality in uncomplicated essential hypertension. Ann Intern Med. 1991;114:345–352[Medline]
  3. Kannel WB. Left ventricular hypertrophy as a risk factor in arterial hypertension. Eur Heart J. 1992;13(Suppl D):82–88
  4. Gueyffier F, Boissel JP, Pocock S, et al. Identification of risk factors in hypertensive patients: contribution of randomized controlled trials through an individual patient database. Circulation. 1999;100:e88–e94[Abstract/Free Full Text]
  5. Lauer MS, Anderson KM, Levy D. Influence of contemporary versus 30-year blood pressure levels on left ventricular mass and geometry: the Framingham Heart study. J Am Coll Cardiol. 1991;18:1287–1294[Abstract]
  6. Bauwens FR, Duprez DA, De Buyzere ML, et al. Influence of the arterial blood pressure and nonhemodynamic factors on left ventricular hypertrophy in moderate essential hypertension. Am J Cardiol. 1991;68:925–929[CrossRef][Medline]
  7. Duprez DA, Bauwens FR, De Buyzere ML, et al. Influence of arterial blood pressure and aldosterone on left ventricular hypertrophy in moderate essential hypertension. Am J Cardiol. 1993;71:17A–20A[CrossRef][Medline]
  8. Harrap SB, Dominiczak AF, Fraser R, et al. Plasma angiotensin II, predisposition to hypertension, and left ventricular size in healthy young adults. Circulation. 1996;93:1148–1154[Abstract/Free Full Text]
  9. Verdecchia P, Reboldi G, Schillaci G, et al. Circulating insulin and insulin growth factor-1 are independent determinants of left ventricular mass and geometry in essential hypertension. Circulation. 1999;100:1802–1807[Abstract/Free Full Text]
  10. Julius S. Effect of sympathetic overactivity on cardiovascular prognosis in hypertension. Eur Heart J. 1998;19(Suppl F):F14–F18
  11. Julius S, Nesbitt S. Sympathetic overactivity in hypertension. A moving target. Am J Hypertens. 1996;9:113s–120s
  12. Mark AL. Regulation of sympathetic nerve activity in mild human hypertension. J Hypertens. 1990;8(Suppl 7):S67–S75[CrossRef]
  13. Esler M, Lambert G, Jennings G. Increased regional sympathetic nervous activity in human hypertension: causes and consequences. J Hypertens. 1990;8(Suppl):S53–S57[CrossRef]
  14. Wallin BG. Assessment of sympathetic mechanisms for recordings of postganglionic efferent nerve traffic. Hainsworth R, Mark AL. Cardiovascular Reflex Control in Health and Disease. Philadelphia, PA: WB Saunders, Co; 1993. p. 65–93
  15. Grassi G, Cattaneo BM, Seravalle G, Lanfranchi A, Mancia G. Baroreflex control of sympathetic nerve activity in essential and secondary hypertension. Hypertension. 1998;31:68–72[Abstract/Free Full Text]
  16. Greenwood JP, Stoker JB, Mary DASG. Single unit sympathetic discharge: quantitative assessment in human hypertensive disease. Circulation. 1999;100:1305–1310[Abstract/Free Full Text]
  17. Macefield VG, Wallin BG, Vallbo AB. The discharge behaviour of single vasoconstrictor motoneurones in human muscle nerves. J Physiol (Lond). 1994;481:799–809[Medline]
  18. Wallin BG, Sundlöf G. A quantitative study of muscle nerve sympathetic activity in resting normotensive and hypertensive subjects. Hypertension. 1979;1:67–77[Abstract/Free Full Text]
  19. Gudbjörnsdóttir S, Lönnroth P, Sverrisdóttir YB, Wallin BG, Elam M. Sympathetic nerve activity and insulin in obese normotensive and hypertensive men. Hypertension. 1996;27:276–280[Abstract/Free Full Text]
  20. Brahimi M, Levy BI, Safar ME, Dabire H. Factors determining cardiac hypertrophy in hypertensive patients with or without peripheral vascular disease. Clin Sci (Colch). 1998;95:261–267[Medline]
  21. Joint National Committee on Prevention, Detection, Evaluation, and Treatment of High Blood Pressure. The sixth report of the Joint National Committee on prevention, detection, evaluation, and treatment of high blood pressure. Arch Intern Med. 1997;157:2413–2446[Abstract]
  22. Sahn DJ, DeMaria A, Kisslo J, Weyman A. Recommendations regarding quantitation in M-mode echocardiography: results of a survey of echocardiographic measurements. Circulation. 1978;58:1072–1083[Abstract/Free Full Text]
  23. Devereux RB, Alonso DR, Lutas EM, et al. Echocardiographic assessment of left ventricular hypertrophy: comparison to necropsy findings. Am J Cardiol. 1986;57:450–458[CrossRef][Medline]
  24. Sundlöf G, Wallin BG. The variability of muscle nerve sympathetic activity in resting recumbent man. J Physiol (Lond). 1977;272:383–397[Abstract/Free Full Text]
  25. Yamada Y, Miyajima E, Tochikubo O, Matsukawa T, Ishii M. Age-related changes in muscle sympathetic nerve activity in essential hypertension. Hypertension. 1989;13:870–877[Abstract/Free Full Text]
  26. Matsukawa T, Gotoh E, Hasegawa O, Shionoiri H, Tochikubo O, Ishii M. Reduced baroreflex changes in muscle sympathetic nerve activity during blood pressure elevation in essential hypertension. J Hypertens. 1991;9:537–542[CrossRef][Medline]
  27. Floras JS, Hara K. Sympathoneural and haemodynamic characteristics of young subjects with mild essential hypertension. J Hypertens. 1993;11:647–655[CrossRef][Medline]
  28. Miyajima E, Yamada Y, Yoshida Y, et al. Muscle sympathetic nerve activity in renovascular hypertension and primary aldosteronism. Hypertension. 1991;17:1057–1062[Abstract/Free Full Text]
  29. Greenwood J, Stoker JB, Mary DASG. Effect of atenolol therapy on peripheral sympathetic nerve discharge in essential hypertension. (abstr)J Hypertens. 1998;16(Suppl 2):S240
  30. Wallin BG, Sundlof G, Stromgren E, Aberg H. Sympathetic outflow to muscles during treatment of hypertension with metoprolol. Hypertension. 1984;6:557–562[Abstract/Free Full Text]
  31. Grassi G, Turri C, Dell’Oro R, Stella ML, Bolla GB, Mancia G. Effect of chronic angiotensin converting enzyme inhibition on sympathetic nerve traffic and baroreflex control of the circulation in essential hypertension. J Hypertens. 1998;16:1789–1796[CrossRef][Medline]
  32. Matsukawa T, Mano T, Gotoh E, Ishii M. Elevated sympathetic nerve activity in patients with accelerated essential hypertension. J Clin Invest. 1993;92:25–28[Medline]
  33. Anderson EA, Sinkey CA, Lawton WJ, Mark AL. Elevated sympathetic nerve activity in borderline hypertensive humans. Evidence from direct intraneural recordings. Hypertension. 1989;14:177–183[Abstract/Free Full Text]
  34. Folkow B. Physiological aspect of primary hypertension. Physiol Rev. 1982;62:347–504[Free Full Text]
  35. Simpson P. Norepinephrine-stimulated hypertrophy of cultured rat myocardial cells is an alpha-1 adrenergic response. J Clin Invest. 1983;72:732–738[Medline]
  36. Sen S, Tarazi RC. Cardiovascular hypertrophy in spontaneously hypertensive rats. J Hypertens. 1986;4(Suppl):S123–S126
  37. Marcus R, Krause L, Weder AB, Mejia AD, Schork NJ, Julius S. Sex-specific determinants of increased left ventricular mass in the Tecumseh blood pressure study. Circulation. 1994;90:928–936[Abstract/Free Full Text]
  38. Kelm M, Schafer S, Mingers S, et al. Left ventricular mass is linked to cardiac noradrenaline in normotensive and hypertensive patients. J Hypertens. 1996;14:1357–1364[CrossRef][Medline]
  39. Wright C, Drinkhill MJ, Hainsworth R. Reflex effects of independent stimulation of coronary and left ventricular mechanoreceptors in anaesthetised dogs. J Physiol (Lond). 2000;528:349–358[Abstract/Free Full Text]
  40. Karim F, Kidd C, Malpus CM, Penna PE. The effects of stimulation of the left atrial receptors on sympathetic efferent nerve activity. J Physiol (Lond). 1972;227:243–260[Abstract/Free Full Text]
  41. Wallin BG, Esler M, Dorward P, et al. Simultaneous measurements of cardiac noradrenaline spillover and sympathetic outflow to skeletal muscle in humans. J Physiol (Lond). 1992;453:45–58[Abstract/Free Full Text]



This article has been cited by other articles:


Home page
CirculationHome page
J. Burns, M. U. Sivananthan, S. G. Ball, A. F. Mackintosh, D. A.S.G. Mary, and J. P. Greenwood
Relationship Between Central Sympathetic Drive and Magnetic Resonance Imaging-Determined Left Ventricular Mass in Essential Hypertension
Circulation, April 17, 2007; 115(15): 1999 - 2005.
[Abstract] [Full Text] [PDF]


Home page
Am. J. Physiol. Heart Circ. Physiol.Home page
H. Murai, S. Takata, M. Maruyama, M. Nakano, D. Kobayashi, K.-i. Otowa, M. Takamura, T. Yuasa, S. Sakagami, and S. Kaneko
The activity of a single muscle sympathetic vasoconstrictor nerve unit is affected by physiological stress in humans
Am J Physiol Heart Circ Physiol, February 1, 2006; 290(2): H853 - H860.
[Abstract] [Full Text] [PDF]


Home page
Nephrol Dial TransplantHome page
R. E. Schmieder
The role of non-haemodynamic factors of the genesis of LVH
Nephrol. Dial. Transplant., December 1, 2005; 20(12): 2610 - 2612.
[Full Text] [PDF]


Home page
J Am Coll CardiolHome page
P. A. Smith, J. F. M. Meaney, L. N. Graham, J. B. Stoker, A. F. Mackintosh, D. A. S. G. Mary, and S. G. Ball
Relationship of neurovascular compression to central sympathetic discharge and essential hypertension
J. Am. Coll. Cardiol., April 21, 2004; 43(8): 1453 - 1458.
[Abstract] [Full Text] [PDF]


Home page
J. Am. Soc. Nephrol.Home page
H. A. Koomans, P. J. Blankestijn, and J. A. Joles
Sympathetic Hyperactivity in Chronic Renal Failure: A Wake-up Call
J. Am. Soc. Nephrol., March 1, 2004; 15(3): 524 - 537.
[Abstract] [Full Text] [PDF]


Home page
CirculationHome page
R. J. Huggett, E. M. Scott, S. G. Gilbey, J. B. Stoker, A. F. Mackintosh, and D. A.S.G. Mary
Impact of Type 2 Diabetes Mellitus on Sympathetic Neural Mechanisms in Hypertension
Circulation, December 23, 2003; 108(25): 3097 - 3101.
[Abstract] [Full Text] [PDF]


Home page
CirculationHome page
M. P. Schlaich, D. M. Kaye, E. Lambert, M. Sommerville, F. Socratous, and M. D. Esler
Relation Between Cardiac Sympathetic Activity and Hypertensive Left Ventricular Hypertrophy
Circulation, August 5, 2003; 108(5): 560 - 565.
[Abstract] [Full Text] [PDF]


Home page
HypertensionHome page
G. Grassi, G. Seravalle, C. Turri, G. Bolla, and G. Mancia
Short-Versus Long-Term Effects of Different Dihydropyridines on Sympathetic and Baroreflex Function in Hypertension
Hypertension, March 1, 2003; 41(3): 558 - 562.
[Abstract] [Full Text] [PDF]


Home page
HypertensionHome page
J. R. Keys, E. A. Greene, W. J. Koch, and A. D. Eckhart
Gq-Coupled Receptor Agonists Mediate Cardiac Hypertrophy Via the Vasculature
Hypertension, November 1, 2002; 40(5): 660 - 666.
[Abstract] [Full Text] [PDF]


Home page
J Am Coll CardiolHome page
P. A. Smith, L. N. Graham, A. F. Mackintosh, J. B. Stoker, and D. A. S. G. Mary
Sympathetic neural mechanisms in white-coat hypertension
J. Am. Coll. Cardiol., July 3, 2002; 40(1): 126 - 132.
[Abstract] [Full Text] [PDF]


Home page
HypertensionHome page
C. Zoccali, F. Mallamaci, G. Tripepi, S. Parlongo, S. Cutrupi, F. A. Benedetto, A. Cataliotti, and L. S. Malatino
Norepinephrine and Concentric Hypertrophy in Patients With End-Stage Renal Disease
Hypertension, July 1, 2002; 40(1): 41 - 46.
[Abstract] [Full Text] [PDF]


This Article
Right arrow Abstract Freely available
Right arrow Figures Only
Right arrow Full Text (PDF)
Right arrow Alert me when this article is cited
Right arrow Alert me if a correction is posted
Services
Right arrow Email this article to a friend
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Download to citation manager
Citing Articles
Right arrow Citing Articles via HighWire
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by Greenwood, J. P.
Right arrow Articles by Mary, D. A. S. G.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Greenwood, J. P.
Right arrow Articles by Mary, D. A. S. G.


HOME SUBSCRIPTIONS CURRENT ISSUE PAST ISSUES CARDIOSOURCE SEARCH HELP FEEDBACK